Vertex Minerals’ new remote control loader has loaded ore from 1438 north stope First firing of high-grade 640 – MIST 1618N stope, with 80t fired of 277t at 16.6g/t Quarter gold sales of $656,708 with ...

Do you appreciate my fitness and nutritional advice? The one arm pushup, commonly abbreviated as OAP, is a great advanced calisthenics exercise to pursue for building lots of strength in the chest, ...

Some things will remain the same for Vertex five years from now, including its dominance in treating cystic fibrosis (CF). However, the company will likely achieve success in several new markets ...

Tutorial recreates Carrot Sulong form from One Piece with flair. Canada's Carney fires back at Trump after Davos speech Cold case murder suspect identified after 51 years Latest weather forecast for ...

Pfizer is racing towards patent cliffs that will lead to even worse financial results. Vertex Pharmaceuticals is posting strong revenue growth and excellent clinical progress. Pfizer's financial ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

Aug 4 (Reuters) - Vertex Pharmaceuticals will stop developing its experimental non-opioid painkiller as a solo treatment after a mid-stage trial failure and will not start a study for expanded use of ...

Aug 4 (Reuters) - Vertex Pharmaceuticals (VRTX.O), opens new tab beat Wall Street estimates for quarterly results on Monday, helped by demand for its new cystic fibrosis drug and product launches.

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the ...

Vertex SME Holdings Limited, a private equity vehicle managed by JMMB Securities Limited, is gearing up to raise another $1 billion to fund its pipeline of investment opportunities. Private equity is ...

Amid a reckoning for the gene therapy field, Vertex Pharmaceuticals has joined a growing list of companies paring back their research efforts around the adeno-associated virus (AAV) vectors used to ...